SCHEMBL427933

SCHEMBL427933

CC(=O)Nc1ccc(OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COC(=O)C(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.49
MEN1 O00255 4/20 0.49
CYP1A2 P05177 2/20 0.45
OPRK1 P41145 2/20 0.45
ADRB2 P07550 2/20 0.45
ADRB1 P08588 2/20 0.45
ADRB3 P13945 2/20 0.45
CYP2D6 P10635 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
MGLL Q99685 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426347 0.90 KMT2A (0.51) KMT2AMEN1CYP1A2OPRK1ADRB2
SCHEMBL425278 0.85 KMT2A (0.46) KMT2AMEN1CYP1A2OPRK1ADRB2
SCHEMBL428554 0.85 KMT2A (0.54) KMT2AMEN1CYP1A2OPRK1ADRB2
SCHEMBL422235 0.83 KMT2A (0.58) KMT2AMEN1CYP1A2OPRK1ADRB2
SCHEMBL29714885 0.74 KMT2A (0.62) KMT2AMEN1CYP1A2OPRK1TSHR
Diacetamate SCHEMBL863106 0.70 KMT2A (0.81) KMT2AMEN1CYP1A2OPRK1TSHR
SCHEMBL1996277 0.69 PDE4A (0.48) KMT2AMEN1SMN1; SMN2HSD17B10LMNA
SCHEMBL19491612 0.68 KMT2A (0.58) KMT2AMEN1CYP1A2TSHRSMN1; SMN2
SCHEMBL14808444 0.68 KMT2A (1.00) KMT2AMEN1CYP1A2OPRK1TSHR
SCHEMBL12291744 0.67 KMT2A (0.75) KMT2AMEN1CYP1A2OPRK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722864-B2 Glycosylated acetaminophen pro-drug analogs NuTek Pharma Ltd. (US) 2014-05-13 US disclosed
US-20130217640-A1 GLYCOSYLATED ACETAMINOPHEN PRO-DRUG NuTek Pharma Ltd. 2013-08-22 US disclosed
US-20120022012-A1 Glycosylated Acetaminophen Pro-Drug Analogs NuTek Pharma Ltd. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022012-A1 Glycosylated Acetaminophen Pro-Drug Analogs UGT1A3, GCG, UGT1A1 KMT2A 4128/4885MEN1 4056/4885CYP1A2 34/4885
US-20130217640-A1 GLYCOSYLATED ACETAMINOPHEN PRO-DRUG UGT1A3, GCG, UGGT1 KMT2A 4023/4885MEN1 4207/4885CYP1A2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.